The prognostic role of red cell distribution width on all-cause and cause-specific outcomes in peripheral T-cell lymphoma: a retrospective cohort study

Abstract

Readily accessible biomarkers for risk stratification in settings with limited resources are lacking. We evaluated the effect of high red distribution width-coefficient of variation (RDW-CV) values (>14%) on all-cause and lymphoma-specific mortality outcomes among 118 patients with peripheral T-cell lymphoma (PTCL) who received systemic treatment at two tertiary centers between 2010 and 2019. With a median follow-up of 45 months, patients with a high RDW-CV had a lower 4-year overall survival rate (34% vs. 45%, p = 0.015) and higher cumulative incidence of lymphoma mortality (54% vs. 34%, p = 0.007). RDW-CV >14% was associated with all-cause (adjusted Hazard Ratio [aHR] 1.98, 95% confidence interval [CI] 1.10–3.56) and lymphoma-specific mortality (aHR 2.64, 95% CI 1.32–5.29). In our study, RDW-CV emerges as an easily accessible and complementary prognostic biomarker for risk stratification among treated patients with de novo PTCL. Further research should validate the predictive role of RDW-CV in prospective cohorts.

Keywords:

• Biomarkers
• lymphoma
• T-cell
• peripheral
• red cell distribution width
• prognosis
• cohort studies

Acknowledgments

The authors thank Dr. Maria del Pilar Quiñones, Dr. Ronald Mendoza, and Dr. Yabar Berrocal for the pathology review.

Author contributions

Denisse Castro: Conceptualization, investigation, data curation, writing- original draft preparation, and final approval of the version to be submitted. Bryan Valcarcel: Conceptualization, methodology and software, writing- original draft preparation, writing- reviewing and editing and final approval of the version to be submitted. Thanya Runciman: writing- original draft preparation, acquisition of data and final approval of the version to be submitted. Yesenia Huerta-Collado: investigation, data curation and final approval of the version to be submitted. Sally Paredes: writing- reviewing and Editing and final approval of the version to be submitted. Brady Beltrán: writing- reviewing and editing, and final approval of the version to be submitted. Jorge J. Castillo: writing- reviewing and editing, and final approval of the version to be submitted. Luis Malpica: writing- reviewing and editing, supervision, and final approval of the version to be submitted.

Disclosure statement

JJC received research funds or consulting fees from Abbvie, AstraZeneca, Beigene, Cellectar, Janssen, Pharmacyclics, Roche, and TG Therapeutics. The rest of the authors declare no conflict of interest.

Data availability statement

Datasets analyzed for the current study are available from the corresponding author upon reasonable request.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.